Dr. Sartor on the Next Steps with Sipuleucel-T for Prostate Cancer

Oliver Sartor, MD
Published: Wednesday, Aug 09, 2017



Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the next steps with sipuleucel-T (Provenge) for patients with prostate cancer.

Cellular studies are still needed to investigate the immune response caused by sipuleucel-T, explains Sartor.

Additionally, studies are needed to determine if immunotherapies are more active in different patient populations, states Sartor.
 


Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the next steps with sipuleucel-T (Provenge) for patients with prostate cancer.

Cellular studies are still needed to investigate the immune response caused by sipuleucel-T, explains Sartor.

Additionally, studies are needed to determine if immunotherapies are more active in different patient populations, states Sartor.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x